keyword
MENU ▼
Read by QxMD icon Read
search

Dotation

keyword
https://www.readbyqxmd.com/read/28435455/the-netpet-score-combining-fdg-and-somatostatin-receptor-imaging-for-optimal-management-of-patients-with-metastatic-well-differentiated-neuroendocrine-tumors
#1
EDITORIAL
Elif Hindié
Neuroendocrine tumors (NET) are often metastatic at the time of diagnosis. Metastatic well-differentiated (G1/G2) NET may display a wide range of behaviors, ranging from indolent to aggressive, even within apparently homogeneous categories. Thus, selecting the optimal treatment strategy is a challenging task. Somatostatin receptor imaging (SRI) is the standard molecular imaging technique for well-differentiated NET. When performed with (68)Ga-labeled somatostatin analogs (SRI-PET), it offers exquisite sensitivity for disease staging...
2017: Theranostics
https://www.readbyqxmd.com/read/28433399/simultaneous-68-ga-dotatate-positron-emission-tomography-magnetic-resonance-imaging-in-meningioma-target-contouring-feasibility-and-impact-upon-interobserver-variability-versus-positron-emission-tomography-computed-tomography-and-computed-tomography-magnetic
#2
J Maclean, N Fersht, K Sullivan, I Kayani, J Bomanji, J Dickson, C O'Meara, S Short
AIMS: The increasing use of highly conformal radiation techniques to treat meningioma confers a greater need for accurate targeting. Several groups have shown that positron emission tomography/computed tomography (PET/CT) information alters meningioma targets contoured by single observers, but whether this translates into improved accuracy has not been defined. As magnetic resonance imaging (MRI) is the cornerstone of meningioma target contouring, simultaneous PET/MRI may be superior to PET/CT...
April 19, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28429044/-68-ga-dotatate-pet-ct-in-recurrent-medullary-thyroid-carcinoma-a-lesion-by-lesion-comparison-with-111-in-octreotide-spect-ct-and-conventional-imaging
#3
Lilian Yuri Itaya Yamaga, Marcelo L Cunha, Guilherme C Campos Neto, Marcio R T Garcia, Ji H Yang, Cleber P Camacho, Jairo Wagner, Marcelo B G Funari
PURPOSE: The aim of this study was to prospectively compare the detection rate of (68)Ga-DOTATATE PET-CT with (111)In-octreotide SPECT-CT and conventional imaging (CI) in medullary thyroid carcinoma (MTC) patients with increased calcitonin (Ctn) levels but negative CI after thyroidectomy. METHODS: Fifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent (68)Ga-DOTATATE PET-CT, (111)In-octreotide SPECT-CT and CI. Histopathology, CI and biochemical/clinical/imaging follow-up were used as the reference standard...
April 20, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28428192/long-term-efficacy-survival-and-safety-of-177lu-dota0-tyr3-octreotate-in-patients-with-gastroenteropancreatic-and-bronchial-neuroendocrine-tumors
#4
Tessa Brabander, Wouter A Van der Zwan, Jaap Jm Teunissen, Boen L R Kam, Richard A Feelders, Wouter W de Herder, Casper H J van Eijck, Gaston J H Franssen, Eric P Krenning, Dik J Kwekkeboom
Purpose<br /> Bronchial and gastroenteropancreatic neuroendocrine tumors (NETs) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogs. We have treated over 1200 patients with peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) since the year 2000 and present the results on efficacy, survival and toxicity of this therapy. <p>Patients and methods<br /> For safety analysis, 610 patients treated with a cumulative dose of at least 100 mCi (3...
April 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28400403/molecular-imaging-in-the-investigation-of-hypoglycaemic-syndromes-and-their-management
#5
David A Pattison, Rodney J Hicks
There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and its integration into patient management. These targets include peptide receptors - somatostatin receptors (SSTR) and glucagon-like peptide-1 receptor (GLP-1R) - the Amine Precursor Uptake and Decarboxylation system utilising the diphydroxyphenylaline (DOPA) analogue 6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine (18F-FDOPA), and glycolytic metabolism with 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)...
April 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28385306/detection-of-atherosclerotic-inflammation-by-68-ga-dotatate-pet-compared-to-18-f-fdg-pet-imaging
#6
Jason M Tarkin, Francis R Joshi, Nicholas R Evans, Mohammed M Chowdhury, Nichola L Figg, Aarti V Shah, Lakshi T Starks, Abel Martin-Garrido, Roido Manavaki, Emma Yu, Rhoda E Kuc, Luigi Grassi, Roman Kreuzhuber, Myrto A Kostadima, Mattia Frontini, Peter J Kirkpatrick, Patrick A Coughlin, Deepa Gopalan, Tim D Fryer, John R Buscombe, Ashley M Groves, Willem H Ouwehand, Martin R Bennett, Elizabeth A Warburton, Anthony P Davenport, James H F Rudd
BACKGROUND: Inflammation drives atherosclerotic plaque rupture. Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET), [(18)F]FDG lacks cell specificity, and coronary imaging is unreliable because of myocardial spillover. OBJECTIVES: This study tested the efficacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET tracer, for imaging atherosclerotic inflammation...
April 11, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28379809/177lu-dotatate-for-midgut-neuroendocrine-tumors
#7
LETTER
Claude Matuchansky
No abstract text is available yet for this article.
April 6, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28379808/177lu-dotatate-for-midgut-neuroendocrine-tumors
#8
LETTER
Jonathan Strosberg, Eric Krenning
No abstract text is available yet for this article.
April 6, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28342392/value-of-the-68-ga-dotatate-pet-ct-in-the-diagnosis-of-endometriosis-a-pilot-study
#9
M Fastrez, C Artigas, N Sirtaine, Z Wimana, M Caillet, S Rozenberg, P Flamen
OBJECTIVE: The non-invasive diagnosis of endometriosis remains challenging. Recent data suggested that somatostatin might be involved in its pathogenesis. High sensitive visualization of somatostatin receptors expression is possible using PET-CT imaging after the administration of a (68)Ga-labeled somatostatin analog (DOTATATE) that will bind to the somatostatin receptor sub-types 2 and 5. The aim of the present study was to assess the usefulness of (68)Ga-DOTATATE PET-CT in the diagnosis of endometriosis...
May 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28341976/development-and-evaluation-of-user-friendly-single-vial-dota-peptide-kit-formulations-specifically-designed-for-radiolabelling-with-68-ga-from-a-tin-dioxide-68-ge-68-ga-generator
#10
Deidré Prince, Daniel Rossouw, Claudia Davids, Sietske Rubow
PURPOSE: This study was aimed to develop single vial 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide kits to be used with fractionated eluates from a SnO2-based (68)Ge/(68)Ga generator. PROCEDURES: Kits were formulated with 35 μg DOTA-Tyr(3)-Thre(8)-octreotide, DOTA-[Tyr(3)]-octreotide and DOTA-[NaI(3)]-octreotide (DOTATATE, DOTATOC and DOTANOC) and sodium acetate powder, vacuum-dried and stored at -20 °C for up to 12 months. Labelling of the kits was carried out with 2 ml (68)Ga eluate...
March 24, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28341900/tumor-induced-osteomalacia-experience-from-a-south-american-academic-center
#11
G González, R Baudrand, M F Sepúlveda, N Vucetich, F J Guarda, P Villanueva, O Contreras, A Villa, F Salech, L Toro, L Michea, P Florenzano
The majority of tumor-induced osteomalacia cases have been reported in the Northern Hemisphere and Asia. In this first series of South American patients, we show that the clinical presentation and sensitivity of plasmatic fibroblast growth factor 23 and somatostatin analog-based imaging are similar to those described in other populations. INTRODUCTION: Describe the experience of clinical presentation, diagnostic study, and treatment of patients with tumor-induced osteomalacia (TIO) in a South American academic center in comparison to literature...
March 25, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28338529/dosimetry-software-hermes-internal-radiation-dosimetry-from-quantitative-image-reconstruction-to-voxel-level-absorbed-dose-distribution
#12
Eero T Hippeläinen, Mikko J Tenhunen, Hanna O Mäenpää, Jorma J Heikkonen, Antti O Sohlberg
OBJECTIVE: The aim of this work is to validate a software package called Hermes Internal Radiation Dosimetry (HIRD) for internal dose assessment tailored for clinical practice. The software includes all the necessary steps to perform voxel-level absorbed dose calculations including quantitative reconstruction, image coregistration and volume of interest tools. METHODS: The basics of voxel-level dosimetry methods and implementations to HIRD software are reviewed...
May 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28336782/functional-imaging-signature-of-patients-presenting-with-polycythemia-paraganglioma-syndromes
#13
Ingo Janssen, Clara Chi Chen, Zhenping Zhuang, Corina M Millo, Katherine Wolf, Alexander Ling, Frank I Lin, Karen T Adams, Peter Herscovitch, Richard A Feelders, Antonio T Fojo, David Taieb, Electron Kebebew, Karel Pacak
Rationale: Pheochromocytoma/paraganglioma (PPGL) syndromes associated with polycythemia have previously been described in association with mutations in the von Hippel-Lindau (VHL) gene. Recently, mutations in the prolyl hydroxylase gene (PHD) 1 and 2 and in the hypoxia-inducible factor 2 alpha (HIF2A) were also found to be associated with multiple and recurrent PPGL. Such patients also presented with PPGL and polycythemia, and later on, some presented with duodenal somatostatinoma. In additional patients presenting with PPGL and polycythemia, no further mutations have been discovered...
March 23, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28332878/three-diagnoses-on-one-gallium-68-dotatate-scan
#14
Run Yu, Andrew Quon, J Randolph Hecht
No abstract text is available yet for this article.
March 23, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28331954/individualised-177-lu-dotatate-treatment-of-neuroendocrine-tumours-based-on-kidney-dosimetry
#15
Anna Sundlöv, Katarina Sjögreen-Gleisner, Johanna Svensson, Michael Ljungberg, Tomas Olsson, Peter Bernhardt, Jan Tennvall
PURPOSE: To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). METHOD: Treatment was given with repeated cycles of 7.4 GBq (177)Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging)...
March 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28320783/pitfalls-in-the-response-evaluation-after-prrt-with-177-lu-dota-0-tyr-3-octreotate
#16
Tessa Brabander, Wouter Van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, R A Feelders, Eric P Krenning, Dik Kwekkeboom
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumour (GEPNETs). However, there are some pitfalls that should be taken into consideration when evaluating the treatment response after PRRT. 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up...
March 20, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28319500/clinical-response-profile-of-metastatic-advanced-pulmonary-neuroendocrine-tumors-to-peptide-receptor-radionuclide-therapy-with-177lu-dotatate
#17
Rahul V Parghane, Sanjay Talole, Kumar Prabhash, Sandip Basu
OBJECTIVES: The aims of this study were to perform multiparametric response assessment of metastatic/advanced pulmonary neuroendocrine tumors (NETs) to Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) (clinical, biochemical, molecular/structural imaging, and survival assessment) and to study the relationship between response, mortality, and overall survival with dual-tracer molecular imaging parameters. METHODS: Twenty-two patients (6 women, 16 men; median age, 44 years; range, 16-72 years) of histopathologically proven pulmonary NETs with metastatic/advanced disease were included and analyzed retrospectively...
March 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28316066/long-term-results-and-tolerability-of-tandem-peptide-receptor-radionuclide-therapy-with-90-y-177-lu-dotatate-in-neuroendocrine-tumors-with-respect-to-the-primary-location-a-10-year-study
#18
Jolanta Kunikowska, Dariusz Pawlak, Marianna I Bąk, Beata Kos-Kudła, Renata Mikołajczak, Leszek Królicki
INTRODUCTION: The peptide receptor radionuclide therapy (PRRT) with (90)Y and (177)Lu is a form of molecular targeted therapy for inoperable or disseminated neuroendocrine tumors (NET). AIM: The aim of the study was to evaluate clinical results and long-term side effects of tandem (90)Y /(177)Lu-DOTATATE therapy in patients with NET. Additionally, we evaluated clinical results with reference to the primary site. MATERIALS AND METHODS: 59 patients with disseminated NET were included in the study prospectively...
March 18, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28289088/association-between-neuroendocrine-tumors-biomarkers-and-primary-tumor-site-and-disease-type-based-on-total-68-ga-dotatate-avid-tumor-volume-measurements
#19
Amit Tirosh, Georgios Z Papadakis, Corina Millo, Samira M Sadowski, Peter Herscovitch, Karel Pacak, Stephen J Marx, Lily Yang, Pavel Nockel, Jasmine Shell, Patience Green, Xavier M Keutgen, Dhaval Patel, Naris Nilubol, Electron Kebebew
OBJECTIVE: To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by (68)Ga DOTATATE PET/CT imaging. DESIGN: A retrospective analysis of a prospective database of patients with NETs. METHODS: Fasting plasma chromogranin A (CgA), neuron-specific enolase (NSE), gastrin, glucagon, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP), and 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were measured...
May 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28271873/gastrointestinal-stromal-tumour-detection-with-somatostatin-receptor-imaging-68-ga-ha-dotatate-pet-ct
#20
Arthur J A T Braat, Roel Goldschmeding, Lodewijk A A Brosens, Menno R Vriens, Bart de Keizer
No abstract text is available yet for this article.
March 2017: Lancet Oncology
keyword
keyword
96892
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"